BML-111

CAT: 0804-HY-100450-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-100450-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
BML-111, a lipoxin A4 analog, is a lipoxin A4 receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2) . BML-111 has antiangiogenic, antitumor and anti-inflammatory properties[1][2].
CAS Number
[78606-80-1]
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Angiotensin-converting Enzyme (ACE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Cancer; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/bml-111.html
Purity
98.87
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
O=C(OC)CCC[C@H](O)[C@H](O)CO
Molecular Formula
C8H16O5
Molecular Weight
192.21
Precautions
H302, H315, H319, H335
References & Citations
[1]Ying Chen, et al. Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: The Role of Antiangiogenesis. Mol Cancer Ther. 2010 Aug;9 (8) :2164-74.|[2]Qiong-Feng Chen, et al. BML-111, a Lipoxin Receptor Agonist, Protects Against Acute Injury via Regulating the Renin Angiotensin-Aldosterone System. Prostaglandins Other Lipid Mediat. 2019 Feb;140:9-17.|[3]T H Lee, et al. Inhibition of Leukotriene B4-induced Neutrophil Migration by Lipoxin A4: Structure-Function Relationships. Biochem Biophys Res Commun. 1991 Nov 14;180 (3) :1416-21.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products